Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis

Abstract

Dalfampridine-ER 5 and 10 mg twice daily did not demonstrate efficacy on the planned endpoint. Post hoc analyses demonstrated significant increases in walking speed relative to placebo with dalfampridine-ER 10 mg. No new safety signals were observed.